**Supplementary Table S5:Univariate and multivariate analysis of PFS according to *PTEN* mutations and clinical features**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | Category | Univariate | Multivariate |
| **HR** | **95% CI** | **P\*** | **HR** | **95% CI** | **P\*** |
| ***PTEN* status** | Mutant/phosphatase domainvs wild-type | 5.38 | 2.19 | 13.19 | <0.001 | 12.61 | 3.75 | 42.35 | <0.001 |
|  | Mutant/C2 domainvs wild-type | 0.55 | 0.20 | 1.51 | 0.243 |  |  |  |  |
| **Age** | ≥ 65 vs < 65 | 1.68 | 0.75 | 3.76 | 0.204 |  |  |  |  |
| **Sex** | Female vs Male | 2.07 | 0.93 | 4.60 | 0.074 | 1.84 | 0.78 | 4.32 | 0.163 |
| **ECOG PS** | 1 vs 0 | 2.37 | 1.06 | 5.31 | 0.035 | 6.07 | 2.04 | 18.01 | 0.001 |
| **Previous treatment regimens** | ≥ 2 vs 1 | 1.57 | 0.67 | 3.64 | 0.299 |  |  |  |  |
| **Liver metastasis** | Yes vs No | 1.83 | 0.73 | 4.61 | 0.197 |  |  |  |  |
| **Lung metastasis** | Yes vs No | 1.20 | 0.41 | 3.52 | 0.735 |  |  |  |  |
| **Lymph node metastasis** | Yes vs No | 0.92 | 0.35 | 2.467 | 0.874 |  |  |  |  |
| **Peritoneal dissemination** | Yes vs No | 0.91 | 0.41 | 2.00 | 0.810 |  |  |  |  |
| **Number of metastatic organs** | ≥ 2 vs 1 | 1.16 | 0.53 | 2.54 | 0.720 |  |  |  |  |
| **Treatment** | Pembrolizumabwith napabucasinvsanti-PD-1 monotherapy | 0.44 | 0.13 | 1.50 | 0.192 |  |  |  |  |

\*P values were calculated using the Cox proportional hazards model.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status CI, confidence interval